The transcriptional activator E2F1 regulates the expression of genes at the G1/S boundary. We have characterized interactions of the E2F1 activation domain with two general transcription factors, the TATA-box binding protein (TBP) and TFIIH. Two distinct binding sites on E2F1 were identi®ed for TBP (amino acids 386 ± 417 and 415 ± 437) each of which supported activation in mammalian cells when expressed as a fusion to a heterologous DNA-binding domain. Neither of these minimal activation domains independently bound TFIIH; rather, the TFIIH binding site of E2F1 overlaps both domains. Loss of TFIIH-binding by E2F1 resulted in a 60 ± 65% reduction in transactivation, suggesting that the E2F1/TFIIH interaction is important, but not essential, for transactivation. The retinoblastoma protein (Rb) binds directly to E2F1 and represses E2F1-mediated transactivation. We have demonstrated that recombinant Rb can compete with TBP and the p62 subunit of TFIIH for binding to immobilized E2F1. A tumorigenic form of Rb de®cient in repressing E2F1-mediated transactivation is likewise de®cient in displacing TBP from E2F1. We propose that competition between Rb and both TBP and TFIIH for binding to E2F1 is a mechanism by which Rb inhibits transactivation by E2F1.
Introduction
The cellular transcription factor E2F is required for transcription from the adenovirus E2 promoter (Kovesdi et al., 1986; Yee et al., 1989) . E2F-binding sites are also present in the promoters of many mammalian genes whose products are involved in cellular proliferation or DNA synthesis, including the promoter of E2F1, the ®rst member of the E2F gene family to be cloned (Blake and Azizkhan, 1989; Hiebert et al., 1989; Mudryj et al., 1990; Pearson et al., 1991; Dalton, 1992; Hamel et al., 1992; Lam and Watson, 1993; Hsiao et al., 1994; Johnson et al., 1994; Neuman et al., 1994) . Members of the E2F protein family bind cooperatively to DNA as heterodimers with members of the DP protein family (reviewed by La Thangue, 1994) , but E2F1 can function as a transcriptional activator on its own (Helin et al., 1992; Kaelin et al., 1992) . Forced expression of E2F1 induces quiescent cells to enter S-phase and this activity correlates with the ability of E2F1 to activate transcription . Recently, E2F1 has been shown to be the product of an oncogene (Xu et al., 1995) , although, paradoxically, mice with a homozygous deletion of the E2F1 gene develop a large range of tumors that is more typical of the loss of a tumor suppressor gene (Yamasaki et al., 1996) .
E2F1 has an acidic activation domain located near its C-terminus which can function even when attached to the DNA-binding domain of a heterologous protein Shan et al., 1992) . Acidic activation domains are found in a large number of yeast and mammalian activator proteins, and many have been shown to function interchangeably between these two systems (reviewed by Hahn, 1993) . In keeping with this observation, E2F1 can function as a transcriptional activator in the yeast S. cerevisiae (Shan et al., 1992; Bandara et al., 1993) .
The analysis of particular transcriptional activators has sometimes revealed the presence of multiple activation domains within a single activator protein (Ma and Ptashne, 1987; Courey and Tjian, 1988; Goodrich et al., 1993; Tanaka and Herr, 1994; Drysdale et al., 1995) . In certain of these cases, activation domains have been demonstrated to consist of minimal activation modules which, when reiterated, result in a synergistic activation of transcription (Tanaka and Herr, 1994; Blair et al., 1996) , but the meaning of this observation has not been clear.
Many transcriptional activation domains have been shown to interact with components of the basal transcriptional machinery. Numerous activator proteins, including the herpes simplex virus transactivator VP16, bind TBP (e.g. see Stringer et al., 1990) , the DNA-binding subunit of the general transcription factor TFIID, and results from mutational studies with several activators, including VP16, have demonstrated a good correlation between the ability of an activator to bind TBP and its ability to activate transcription (Ingles et al., 1991; Seto et al., 1992; Truant et al., 1993; Melcher and Johnston, 1995) . Interactions have also been reported between certain transcriptional activators and TFIIB Ing et al., 1992) , with certain TBP-associated factors (TAFs) (Goodrich et al., 1993; Hoey et al., 1993; Lu and Levine, 1995; Thut et al., 1995) , and also with TFIIF (Zhu et al., 1994; Joliot et al., 1995) . In addition, VP16 has been shown to interact indirectly with TFIIA through an interaction with the coactivator PC4 (Ge and Roeder, 1994b) . We have previously shown that VP16 and the human anti-oncogenic transactivator p53 bind to the general transcription factor TFIIH and that mutations in VP16 that compromise transactivation by VP16 correlate with a decrease in its ability to bind TFIIH (Xiao et al., 1994) . TFIIH is a multisubunit factor containing DNA helicase activities (Schaeer et al., 1993; Serizawa et al., 1993) and a cyclin-dependent protein kinase that can phosphorylate the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (Feaver et al., 1991; Gileadi et al., 1992; Lu et al., 1992; Serizawa et al., 1992) . There is evidence that TFIIH is involved in the melting of the promoter DNA upstream of the transcriptional initiation site (Pan and Greenblatt, 1994; Tantin and Carey, 1994; Holstege et al., 1996) . Through phosphorylation of the CTD, TFIIH may also be involved in the transition from an initiation complex to an elongation complex and in promoter escape (Parvin and Sharp, 1993; Goodrich and Tjian, 1994; Pan and Greenblatt, 1994; O'Brien et al., 1994) . Promoter escape, which is distinct from the formation of the ®rst phosphodiester bond and typically occurs about 10 ± 40 nucleotides downstream of the initiation site (O'Brien et al., 1994) , may be de®ned as the moment when elongation by RNA polymerase becomes rapid, ecient and irreversible.
Targets of activation domains other than general transcription factors have also been identi®ed. The activation domains of VP16 and GAL4 interact with RPA (He et al., 1993) . RPA is a single-stranded DNAbinding protein that is thought to bind to melted DNA at origins of replication (reviewed in Challberg and Kelly, 1989; Stillman, 1989; So and Downey, 1992) . Certain transcriptional activators, including VP16 and GAL4, can stimulate DNA replication (reviewed in He et al., 1993) , and one mechanism proposed for how this may occur is through recruitment of components of the replication machinery, such as RPA, to origins of DNA replication.
Transcriptional activation by E2F1 is negatively regulated by the retinoblastoma protein. Introduction of Rb into an Rb-negative cell line leads to growth arrest that correlates with the ability of Rb to interact with E2F1 (Qin et al., 1992; Hiebert, 1993) . The retinoblastoma protein binds directly to the activation domain of E2F1 and inhibits transactivation. In addition to inhibiting the activity of E2F1, Rb can itself directly inhibit transcription. When Rb is tethered to DNA upstream of a promoter, either through an interaction with DNA-bound E2F, or via a heterologous DNA-binding domain, Rb can actively repress transcription (Weintraub et al., 1992 (Weintraub et al., , 1995 Bremner et al., 1995) . Oncogenic forms of the retinoblastoma gene often result in the expression of deleted or substituted forms of the protein which are de®cient in their ability to bind to and inhibit the activity of E2F1. It has also been demonstrated that several viral oncoproteins such as SV40 T-antigen and adenovirus E1A, bind to the retinoblastoma protein and that this interaction precludes the interaction of Rb and E2F1. These observations highlight the importance of the Rb/E2F1 interaction for normal control of cellular proliferation. The disruption of this interaction would thereby lead to the deregulation of E2F1 activity and contribute to oncogenesis (reviewed by Nevins, 1992) .
The activation domain of E2F1 has previously been demonstrated to interact with in vitro translated human TBP, and both activation and TBP-binding required the Rb-binding region (amino acids 409 ± 426) of E2F1 (Hagemeier et al., 1993) . Mutational analysis identi®ed a number of double and triple mutations that had modest eects on transactivation by E2F1. Although some of these mutations had similar, modest eects on the binding of TBP, the correlation was not perfect. In particular, certain mutations in E2F1 that caused a decreased level of transactivation led to increased binding of TBP. These results could be explained by existence of other targets for E2F1. For example, it is plausible that such mutations might alter the structure of the E2F1 activation domain such that the anity for TBP is increased but that, at the same time, the interaction of E2F1 with at least one other relevant In this paper we have further dissected the activation domain of E2F1 and identi®ed minimal binding domains for TBP and TFIIH, including two independent binding sites for TBP. To assess the importance of these interactions for the ability of E2F1 to activate transcription, fragments of the activation domain of E2F1 were expressed as fusions to the DNA-binding domain of yeast GAL4 (GAL4DBD) and assayed for transcriptional activation in mammalian cells. In this way we were able to correlate transactivation with the ability to bind TFIIH and TBP. We have also used a competition experiment based on protein anity chromatography to show that Rb can directly inhibit the interactions of E2F1 with TBP and the p62 subunit of TFIIH.
Results
The E2F1 activation domain is contained within amino acids 368 ± 437 . In order to study the mechanism of transcriptional activation by E2F1 we set out to identify the minimal portions of the E2F1 activation domain that could bind various general transcription factors and activate transcription. To do so we initially carried out protein anity chromatography experiments (Formosa et al., 1991) and in vitro binding experiments using GST-fusion proteins containing portions of the E2F1 activation domain. The GST-fusion proteins used as ligands in these experiments are shown in Figure 1 . The purities of all these proteins were similar after overproduction in E. coli and puri®cation by glutathione-sepharose chromatography.
Identi®cation of general factors that interact with the activation domain of E2F1
Initially, HeLa whole cell extract was applied to columns containing either immobilized GST or GST-E2F1(342 ± 437) and bound proteins were eluted sequentially with anity chromatography buer (ACB) containing 1 M NaCl and 0.1% SDS. E2F1 contains an acidic activation domain and a number of such transactivators, including VP16, have been shown to interact with general transcription factors, including TBP (Stringer et al., 1990) , TFIIB and TFIIH (Xiao et al., 1994) . Therefore, we tested the GST-E2F1(342 ± 437) column eluates for the presence of these factors to compare the targets of the E2F1 activation domain with those of previously characterized activation domains. The column eluates were subjected to SDS ± PAGE and analysed by Western blotting with antisera against human TBP or TFIIB, or with monoclonal antibody M.Ab3c9 directed against the p62 subunit of human TFIIH (Fischer et al., 1992) . Human TBP was detected in the SDS eluate from the GST-E2F1 column, presumably re¯ecting the binding of TFIID from the extract, but not in the SDS eluate from the GST control column (Figure 2 , top panel, lanes 4 and 5). Upon longer exposure, a smaller amount of TBP was also present in the salt eluate from the GST-E2F1 column and not in the control column eluate (data not shown). When we analysed the same GST and GST-E2F1 column eluates by Western blotting with antiserum against human TFIIB, no TFIIB was readily detected in any of the column eluates (Figure 2, middle panel) . After a very long exposure of the Western blot, a trace amount of TFIIB was present in both the salt and SDS eluates of the GST-E2F1 column (data not shown), but the signi®cance of this very small amount of TFIIB binding to E2F1 is not clear. When the eluates were analysed for the presence of TFIIH, the TFIIH subunit p62 was clearly present in the GST-E2F1(342 ± 437) eluates (Figure 2 , bottom panel, lanes 3 and 5), but not in the control column eluates (lanes 2 and 4). We Salt SDS Figure 2 The activation domain of E2F1 selectively retains human TBP and TFIIH from a HeLa whole cell extract. Eight hundred microlitres of HeLa whole cell extract (WCE) were applied to a 40 ml control GST column or a GST-E2F1 (342 ± 437) anity column. The columns were washed with 10 column volumes of ACB containing 0.1 M NaCl and sequentially eluted with four column volumes of ACB containing 1.0 M NaCl and with four column volumes of 0.1% SDS. The salt and SDS eluates were visualized by Western blotting with antisera (UBI) directed against human TBP (upper panel), human TFIIB (middle panel), and a monoclonal antibody M.Ab3c9 (Fischer et al., 1992) directed against the p62 subunit of TFIIH. Detection was by the ECL method (Amersham). Lane 1, 5 ml of HeLa whole cell extract used to load the columns; lane 2, 20 ml of 1.0 M NaCl eluate from the GST column; lane 3, 20 ml of 1.0 M NaCl eluate from the GST-E2F1 (342 ± 437) column; lane 4, 20 ml of 0.1% SDS eluate from the GST column; lane 5, 20 ml of 0.1% SDS eluate from GST-E2F1 (342 ± 437) column therefore focused our attention on characterizing the E2F1/TBP and E2F1/TFIIH interactions. Because TFIID and TFIIH are both multisubunit factors, the possibility existed that only the TBP and p62 individual subunits of these factors were present in the GST-E2F1 eluates, and not the corresponding multisubunit factors. To address this question we analysed the eluates by Western blot with antibodies directed against various subunits of TFIID and TFIIH. We detected TAF II 70 in the GST-E2F1 eluates using a monoclonal antibody directed against this subunit (Santa Cruz), indicating that TFIID can interact with the activation domain of E2F1 (data not shown). We also found by Western blotting that the p89 and cdk7 subunits of TFIIH (Santa Cruz and UBI, respectively) were also present in the GST-E2F1 eluates, demonstrating that the GST-E2F1 anity column bound TFIIH from the HeLa whole cell extract (data not shown).
Interaction of E2F1 with yeast TFIIH
Since the E2F1 activation domain can function in yeast (Shan et al., 1992; Bandara et al., 1993) mammalian cells, we predicted that E2F1 would also bind yeast TFIIH. To test this idea we chromatographed yeast whole cell extract over a GST-E2F1(342 ± 437) column and eluted the column with ACB containing 1 M NaCl. The eluates were analysed by SDS ± PAGE followed by Western blotting with antiserum raised against GST-TFB1 (Figure 3a) . The TFB1 protein is the yeast homologue of human p62 and a subunit of yeast TFIIH. It was detected in the GST-E2F1 column eluate (lane 3) but not in the control GST column eluate (lane 2), indicating that yeast TFIIH also binds the activation domain of E2F1. The lower molecular weight cross-reacting bands observed in lanes 2 and 3 in this experiment correspond to the GST and GST-E2F1(342 ± 437) column ligands, some of which dissociated from the columns during the elution step and were recognized by anti-GST antibody.
Interaction of the activation domain of E2F1 with TFIIH subunits
Yeast TFIIH consists of a core of ®ve polypeptides (TFB1, TFB2, TFB3, SSL1 and RAD3), the DNA helicase subunit SSL2, and a multisubunit kinase component, TFIIK (Feaver et al., 1995) . To identify a subunit of yeast TFIIH that could mediate the E2F1/ TFIIH interaction, we expressed four of the yeast TFIIH subunits in vitro in the presence of 35 S-labeled methionine using a coupled transcription/translation system containing rabbit reticulocyte lysate and phage T7 RNA polymerase. These lysates containing the various labeled proteins were then each separately incubated with either GST or GST-E2F1(342 ± 437) immobilized on glutathione beads. After extensive washing the bound proteins were eluted with ACB containing 1 M NaCl. The input and eluted proteins were analysed by SDS ± PAGE followed by autoradiography. Of the four subunits that were tested, only TFB1 was clearly retained on the GST-E2F1 column ( Figure 3b , lane 3). These results do not, however, rule out the possibility that E2F1 also interacts with a dierent subunit of yeast TFIIH that we did not test in this experiment.
We also tested some of the human homologues of the yeast TFIIH subunits. Using a similar approach to that described for the analysis of the yeast factors, we observed interactions between E2F1 and both p62, which is the human homologue of yeast TFB1 ( Figure  3c , compare lanes 3 and 5 with lanes 2 and 4), and p89, which is the human homologue of yeast SSL2 (compare lanes 8 and 10 with lanes 7 and 9). Similar proportions of the loaded material were retained on the GST-E2F1 column for these two subunits, although the binding of both was relatively weak.
Mapping of the TFIIH-binding site in E2F1
We next mapped the binding site for TFIIH in E2F1. A series of protein anity columns were prepared containing as column ligands various portions of the E2F1 activation domain expressed as GST-fusion proteins. For this experiment we used the human TFIIH that is present in a HeLa whole cell extract. All the columns were loaded with extract, washed with ACB containing 0.1 M NaCl and eluted with ACB containing 1 M NaCl. The column eluates were analysed by SDS ± PAGE followed by Western blotting with the monoclonal antibody M.Ab3c9 directed against the p62 subunit of human TFIIH (Fischer et al., 1992) (Figure 4a ). As was the case for Fifty microlitres of E. coli extract containing recombinant yeast TBP (lanes 3 and 6) or lacking TBP (lane 5), or no extract at all (lanes 2 and 4), were applied to 10 ml control GST columns or to 10 ml GST-E2F1 (342 ± 437) anity columns. The columns were then washed with 10 column volumes of ACB containing 0.1 M NaCl and eluted with four column volumes of ACB containing 0.5 M NaCl. Half of each eluate was subjected to SDS ± PAGE and visualized by silver staining. Lane 1, 1/5 of the TBPcontaining extract used as load; lane 2, eluate from GST column, no extract loaded, lane 3, eluate from GST column, yeast TBPcontaining extract loaded; lane 4, eluate from GST-E2F1 (342 ± 437) column, no extract loaded; lane 5, eluate from GST-E2F1 (342 ± 437) column, control extract lacking TBP loaded; lane 6, eluate from GST-E2F1 (342 ± 437) column, yeast TBP-containing extract loaded. The positions of protein molecular weight standards are indicated at the right also resulted in the loss of binding of TFIIH (lane 7). Therefore the TFIIH-binding site of E2F1 is contained within amino acids 409 ± 437.
For comparison, we also mapped the TFB1-binding site in E2F1. We used various portions of the E2F1 activation domain fused to GST, and 35 S-labeled TFB1 expressed in vitro in the presence of 35 S-labeled methionine using a rabbit reticulocyte lysate coupled transcription/translation system. The input and bound proteins were analysed by SDS ± PAGE followed by autoradiography (Figure 4b ). In this experiment amino acids 409 ± 437 of E2F1 bound TFB1 (lane 5), and neither amino acids 415 ± 437 (lane 6) nor amino acids 386 ± 426 (lane 8) were able to do so. Therefore, the same minimal portion of E2F1 (amino acids 409 ± 437) that was necessary and sucient for binding human TFIIH was also necessary and sucient for binding yeast TFB1.
Interaction of the E2F1 activation domain with human and yeast TBP
Since the binding by an acidic activator protein of TBP from a human cell extract could re¯ect either an interaction of the activator with TAFs (described in Pugh and Tjian, 1992) or with TBP, or both, we used Far Western blotting to show that E2F1 interacts speci®cally with in vitro translated human TBP (see Figure 5a ). Similar observations were reported by Hagemeier et al. (1993) using in vitro binding experiments. In our experiments, one microgram of GST or GST-E2F1(342 ± 437) protein was mixed with an E. coli extract (35 mg protein) and electrophoresed on an SDS-polyacrylamide gel. The gel was either stained with Coomassie brilliant blue for visualization of proteins or transferred to nitrocellulose for Far Western analysis (Figure 5a ).
35
S-methionine-labeled human TBP produced in vitro using a rabbit reticulocyte lysate coupled transcription/translation system bound speci®cally to the activation domain of E2F1 (Figure 5a , lane 4). Although weak binding of human TBP to E. coli proteins was also detected, the binding of human TBP to GST-E2F1 was highly selective, since, as is apparent upon inspection of Figure 5a , the band corresponding to GST-E2F1, which was not the most prominant band on the Coomassie-stained gel (lanes 1 and 2), became the most prominant band in the Far Western experiment (lanes 3 and 4). These results indicated that the TBP/ E2F1 interaction is not dependent on TBP being in a complex with TAFs, but did not rule out the possibility that E2F1 contacts one of the TAFs as well as TBP.
TBP is a highly conserved molecule (reviewed by Greenblatt, 1991) and certain activation domains, including those of VP16 and p53, that have been shown to bind human TBP can also bind yeast TBP if they are able to function in S. cerevisiae (Stringer et al., 1990; Liu et al., 1993; Martin et al., 1993; Truant et al., 1993) . We expected the same to be true of the E2F1 activation domain and tested whether it could bind the yeast TBP in a yeast whole cell extract. To do so we analysed the column eluates used in Figure 3a by Western blotting with antiserum against yeast TBP and found that TBP was indeed present in the E2F1 eluate (Figure 5b ).
We also tested whether E2F1 could directly bind yeast TBP and whether this interaction had the speci®city and selectivity expected for a biologically important interaction. An E. coli extract containing yeast TBP (Figure 5c , lane 1), or a control extract lacking yeast TBP (not shown), was applied to a series of anity columns. Proteins that bound to these columns were eluted with buer containing 0.5 M NaCl and the eluates were analysed by SDS ± PAGE followed by staining with silver. A 27 kDa polypeptide the size of yeast TBP eluted from a GST-E2F1 column that was loaded with yeast TBP-containing extract (lane 6), but not from a GST control column loaded with the same extract (lane 3). This polypeptide was not eluted from an E2F1 column that was loaded with a control extract lacking yeast TBP (lane 5), con®rming that the polypeptide retained speci®cally by the GST-E2F1 column was indeed yeast TBP. No E. coli proteins were detected in the eluates from the GST-E2F1 columns, demonstrating that the binding of yeast TBP by E2F1 is highly selective. These results are consistent with a report demonstrating that the activation domain of E2F1 could be cross-linked to yeast TBP at a TATA-containing promoter (Emili and Ingles, 1995) .
Mapping of the TBP-binding sites in E2F1
To localize the minimal TBP-binding domain of E2F1, we used GST-fusion proteins containing various portions of the activation domain of E2F1 as ligands for anity chromatography. The columns were loaded with an E. coli extract containing yeast TBP and the high salt eluates were analysed by SDS ± PAGE followed by Western blotting with antibody against yeast TBP. As shown in Figure 6a , residues 415 ± 437 of E2F1 were sucient to bind yeast TBP (lane 6). Neither a fragment containing amino acids 427 ± 437 of E2F1 (Figure 6a , lane 7) nor one containing amino acids 415 ± 426 (lane 8) was sucient to bind yeast TBP beyond that which was observed with the GST control column (lane 2). When a series of carboxy-terminal deletions of E2F1 were tested for their abilities to bind TBP (Figure 6b ), a fusion protein that retained amino acids 386 ± 426 of E2F1 (lane 4) bound the same amount of yeast TBP as a version containing an intact carboxy-terminus (lane 3). A further truncation of E2F1 to amino acid 417 (lane 5) also retained binding to TBP, although less TBP was bound in this case. Truncation to amino acid 408 abolished the binding of TBP (lane 6). These results indicated that the activation domain of E2F1 has two independent motifs, amino acids 386 ± 417 and 415 ± 437, that can bind yeast TBP (see Figure 7) .
Transactivation by fragments of E2F1
To assess the relative importance of binding TBP and TFIIH we measured the transactivation potential of the portions of E2F1 that we used for our binding studies. For this purpose we constructed a series of GAL4-E2F1 expression plasmids for assay in transfected mammalian cells. Because transactivation by E2F1 is negatively regulated through direct binding of the retinoblastoma protein to the activation domain of E2F1 (Hiebert et al., 1992; Flemington et al., 1993; Helin et al., 1993) , we used the Rb-negative cell line C-33A in our transfection experiments. To examine the expression level of each GAL4-E2F1 fusion protein that we used in our transfection experiments we prepared cell lysates from the transfected cells and immunoprecipitated with antiserum directed against the DNA-binding domain of GAL4(GAL4DBD). We also cotransfected an expression vector for b-galactosidase as an internal control. The immune complexes were analysed by Western blotting with a monoclonal antibody also directed against the DNA-binding domain of GAL4. To correct for dierences in transfection eciency we normalized the amount of sample loaded on the gel to the level of b-galactosidase activity that was measured (Figure 8a ). We detected similar expression levels of all the GAL4-E2F1 fusion proteins in C-33A cells except the one corresponding to GAL4-E2F1(427 ± 437)(lane 9). We have never been able to detect expression of this fusion protein even when we used 6 times as much sample.
The results of the transient transfection experiments are presented graphically in Figure 8b . Our reporter construct, E1B-CAT (Lillie and Green, 1989), contained ®ve GAL4-binding sites upstream of the adenovirus E1B promoter driving the expression of the E. coli chloramphenicol acetyltransferase gene. Analysis of the C-terminal deletion series of the E2F1 activation domain revealed that truncation to amino Levels of transcription are indicated as a percentage of the level of activity measured for the construct that gave the highest level of activity, the one encoding GAL4-E2F1 (386 ± 437). Typically, transfection of this construct resulted in approximately 500-fold activation under these conditions. The relative amounts of activity of the various constructs were independent of the DNA concentration used in the transfection experiments over a broad range (data not shown) acid 426 reduced activation to approximately 35% of the activity produced by amino acids 386 ± 437, while truncation to amino acid 417 reduced activation to 5%. The N-terminal deletion series revealed that amino acids 409 ± 437 and 415 ± 437 produced 47% and 19%, respectively, of the level of activation measured for GAL4-E2F1(386 ± 437). Neither of the two smallest fragments that we tested, 415 ± 426 and 427 ± 437, was able to activate transcription in our assay. In the case of GAL4-E2F1(427 ± 437), however, we were not able to detect expression of this protein in the C-33A cells (Figure 8a) . The activation and binding data are summarized in Table 1 . Interestingly, all of the fragments of E2F1 that retained the ability to bind TBP were able to activate transcription, albeit to varying degrees. The data also indicated that two independent activation modules, amino acids 386 ± 417 and 415 ± 437, each of which can bind TBP, are contained within the E2F1 activation domain. These results support the notion that the E2F1/TBP interaction is biologically signi®cant. When only a single, weak, TBP-binding site was present (amino acids 386 ± 417), activation was particularly weak. When both TBP-binding sites were present (i.e. the intact activation domain) they functioned synergistically to activate transcription. Since neither of the two minimal activation domains bound TFIIH, we have concluded that the E2F1/TFIIH interaction is not essential for transactivation by E2F1. Nevertheless, a loss in the binding of TFIIH correlated with a reduction in transactivation of 60 ± 65%, suggesting that the E2F1/TFIIH interaction does play a role in the eciency of transactivation by E2F1. We also found that there was a 50% dierence in the level of transactivation between GAL4-E2F1(386 ± 437) and GAL4-E2F1(409 ± 437). Both of these fragments of E2F1 bind TBP and TFIIH. Perhaps they dier in the level of transactivation because there are two TBPbinding sites in the E2F1 fragment 386 ± 437 versus one site in 409 ± 437. Alternatively, there may be another target of the E2F1 activation domain, such as MDM2 (Martin et al., 1995) , a TAF or some as yet unidenti®ed co-factor, that binds the larger fragment, but not the smaller one, and is responsible for the dierence in the level of transactivation.
The eects of single amino acid substitutions in E2F1
Upon observing that removal of the N-terminal 6 amino acids from fragment 409 ± 437 of E2F1 resulted in the loss of binding of TFIIH, we expected that certain of these amino acids must be important for the binding of TFIIH to E2F1. Therefore three separate substitutions at amino acid positions 411, 412 and 413 were introduced into a vector that expresses GST-E2F1(409 ± 437). HeLa whole cell extract was chromatographed on GST, GST-E2F1(409 ± 437)wt, GST-E2F1(409 ± 437)Y411A, GST-E2F1(409 ± 437)H412P and GST-E2F1(409 ± 437)F413A protein anity columns. The eluates were analysed by SDS ± PAGE followed by Western blotting with a monoclonal antibody M.Ab3c9 directed against the p62 subunit of human TFIIH (Fischer et al., 1992) (Figure 9a) . The substitutions at positions 411 and 413 did not abolish binding to TFIIH but did result in substantially less TFIIH being retained on the columns (Figure 9a ), lanes 4,6,9 and 11). However, the histidine to proline substitution at position 412 greatly increased the amount of TFIIH retained on the column (compare lanes 3 and 5). When compared to standards electrophoresed on the same gel there was clearly more than 10 times as much TFIIH bound by GST-E2F1(409 ± 437)H412P than by the wild type form of the protein (data not shown). In contrast, the H412P substitution had no eect on the binding of TBP (Figure 9b) .
We then tested what eect this substitution at position 412 had on transactivation in transient transfection experiments. Western blotting revealed that GAL4(409 ± 437)H412P was expressed at a level twofold less than the wild type version of this protein (Figure 9c ), and this fact was taken into account in analysing the activation data. With a reporter construct containing ®ve GAL4-binding sites, we found no signi®cant dierence in the levels of transactivation measured for the wild type and mutant proteins (data not shown). This result was not completely surprising as there have been previous reports that single amino acid substitutions in the activation domain of E2F1 have little eect when the reporter gene contains multiple binding sites for the activator (Hagemeier et al., 1993) . With a reporter construct containing a single GAL4-binding site upstream of the SV40 early promoter, we observed a threefold increase in transactivation caused by the H412P mutation (Figure 9d) . These results further supported the notion that the interaction of E2F1 with TFIIH can be biologically signi®cant.
The eect of Rb on the interactions of E2F1 with TBP and p62
Transactivation by E2F1 is repressed when Rb is bound to its activation domain (Arroyo and Raychaudhuri, 1992; Hiebert et al., 1992; Flemington et al., 1993; Helin et al., 1993) . Illustrated in Figure 7 are the portions of E2F1 that bind Rb and TBP. They overlap substantially, raising the possibility that Rb competes with TBP for binding to the activation domain of E2F1. To test this possibility, we used GST-fusion proteins containing amino acids 379 ± 928 of Rb, which includes the portion of Rb (amino acids 379 ± 870) required for maximal binding to E2F1 (Qian et al., Either GST, GST-E2F1 (409 ± 437) wild type or variants thereof were used as column ligands in anity chromatography experiments like those described in Figure 2 . The eluates were analysed by SDS ± PAGE followed by Western blotting with monoclonal antibody M.Ab3c9 (Fischer et al., 1992) 1992; Hiebert, 1993) . A typical result is shown in Figure 10a . A series of anity columns was prepared containing immobilized GST-E2F1(342 ± 437) (lanes 1,2 and 3) or, as a control, a GST-VP16(413 ± 490) fusion protein containing the activation domain of herpes simplex virus VP16 (lane 4). We demonstrated previously that the activation domain of VP16 also binds yeast TBP directly and selectively (Stringer et al., 1990; Ingles et al., 1991) . An E. coli extract containing yeast TBP was applied to each column and the columns were subsequently washed with low salt buer and then eluted with either GST or GST-Rb, as indicated in the Figure. The eluates were analysed by Western blotting with antibody against TBP. No yeast TBP was eluted from the GST-E2F1 anity column by GST (lane 1). In contrast, yeast TBP was eluted from the GST-E2F1 column by wild type Rb (lane 2). Compared with wild type Rb, the C706F mutant form of Rb, which is defective in binding E2F1 (Arroyo and Raychaudhuri, 1992; Hiebert et al., 1992) , showed a marked decrease (3 ± 4-fold, as judged by comparison to known amounts of TBP run as standards on the gel) in its ability to elute yeast TBP from the GST-E2F1 column (lane 3). The ability of Rb to displace TBP from E2F1 was speci®c for the activation domain of E2F1, since only a trace amount of yeast TBP was eluted by Rb from the GST-VP16 column (lane 4), even though as much yeast TBP was initially bound to the GST-VP16 column as to the GST-E2F1 columns (data not shown). Therefore, our results supported a model whereby Rb inhibits transactivation by E2F1 by interfering with the interaction between E2F1 and TBP. This concept was strengthened by our ®nding that a naturally occurring tumorigenic form of Rb (C706F) competes poorly with TBP for binding to E2F1. The Rb-binding site in E2F1 also overlaps the TFIIH binding site. We therefore tested whether Rb could compete, as well, with TFIIH for binding to E2F1. For this experiment GST or GST-E2F1(342 ± 437) protein was immobilized on glutathione-Sepharose beads. The beads were incubated ®rst with blocking buer containing BSA and then with either BSA (Figure 10b, lane 4) or Rb (amino acids 379 ± 792) (lane 5) in ACB containing 0.1 M NaCl. After incubation with BSA or Rb for an hour, reticulocyte lysate containing 35 S-labeled p62 was added to each tube. The beads were subsequently washed with low salt buer and bound proteins were eluted with high salt. As before (Figure 3c ), p62 bound speci®cally to GST-E2F1 (compare lanes 2 and 3). In contrast, preincubation of the GST-E2F1 beads with Rb inhibited the binding of p62 (compare lanes 4 and 5). Similar results were obtained with TFB1, the yeast homologue of p62 (data not shown). Therefore, the interaction of Rb with the activation domain of E2F1 prevents the binding of p62.
Discussion
Our results demonstrate that the activation domain of E2F1 has two subdomains (amino acids 415 ± 437 and 386 ± 417) that can function independently and independently bind TBP. The presence within a single transcription factor of redundant modules that can Fifty microlitres of an E. coli extract containing yeast TBP were applied to 5 ml GST-E2F1 (342 ± 437) anity columns (lanes 1,2,3) or a GST-VP16 (413 ± 490) anity column (lane 4). The columns were washed with 15 column volumes of low salt buer and then eluted with low salt buer containing 50 mg of the indicated protein in a volume of 100 ml. The eluates were analysed by Western blotting with an antiserum directed against yeast TBP. Lane 1, elution with GST of E2F1 column; lane 2, elution with wild type GST-Rb (379 ± 928) of E2F1 column, lane 3, elution with mutant GST-Rb (379 ± 928) (C706F) of E2F1 column; lane 4, elution with wild type GST-Rb (379 ± 928) of VP16 column. (b) Rb prevents p62 from binding E2F1. Ten microlitres of glutathione-sepharose beads containing either immobilized GST or GST-E2F1 (342 ± 437) at a concentration of 4 mg/ml were incubated at 48C for 1 1/2 h in ACB containing 2 mg/ml BSA, 0.5% Triton X-100 and 0.1 M NaCl. Then this buer was either left (lanes 2 ± 3), or replaced with either a 0.75 mg/ml solution of Rb protein (amino acids 379 ± 792) in ACB containing 0.1 M NaCl (lane 5), or this same buer containing 2 mg/ml BSA (lane 4). All tubes were incubated for another hour and then 10 ml of reticulocyte lysate containing 35 Slabeled p62 was added to each tube. After an hours incubation the beads were washed in low salt buer and then eluted with high salt. One quarter of each eluate was loaded on the gel independently bind TBP and activate transcription has been observed previously in Sp1 (Emili et al., 1994) . Indeed, there is evidence that reiteration of a minimal activating module as short as 11 amino acids provides all the information necessary to interact with TBP and support transcriptional activation (Blair et al., 1994) . We were not able to detect binding of TFIIH to either of the two minimal TBP-binding sites of E2F1, although the TFIIH-binding site, consisting of amino acids 409 ± 437, overlaps both of them. Figure 7 shows a schematic representation of the binding sites for TBP and TFIIH within the activation domain of E2F1. It is curious, but not entirely unexpected, that the extension of a TBP-binding site in E2F1 can create binding sites for TFIIH and Rb. In a similar fashion, truncation of the VP16 activation domain to amino acid 456 creates a weakened activator (Triezenberg et al., 1988; Regier et al., 1993; Walker et al., 1993) that can still bind TBP (Ingles et al., 1991) , but no longer binds TFIIH (Xiao et al., 1994) . Therefore, the presence of multiple activation modules may not simply be a matter of multimerizing binding sites for one particular target, but may, in fact, form a distinct surface for another target.
We found that E2F1 is able to bind yeast, as well as human, TFIIH. The fact that E2F1 activates in yeast and also binds yeast TFIIH further suggests that an interaction of E2F1 with TFIIH is biologically important. We also showed that the same fragments of E2F1 that bind TFIIH bind TFB1, the yeast counterpart of the p62 subunit of human TFIIH. Although we have not tested all of the subunits of TFIIH for binding to E2F1, this similarity in the way E2F1 binds TFIIH and TFB1 suggests that TFB1 (or p62) may mediate the interaction of E2F1 with TFIIH. Both VP16 and p53 bind TFIIH and each of these acidic activation domains also binds human p62 and yeast TFB1 (Xiao et al., 1994) . Thus, interaction with this subunit of TFIIH may be a common feature of acidic activators. We also observed an interaction of E2F1 with human ERCC3 (p89) but little binding to its yeast equivalent, SSL2. p53 has been shown to bind the ERCC3 and ERCC2 subunits of TFIIH along with p62 (Wang et al., 1994 (Wang et al., , 1995 Xiao et al., 1994) . The interaction of p53 with RAD3, the yeast equivalent of ERCC2, is weaker than its interaction with the human subunit, and mutations in p53 dierentially aect the binding of RAD3 and ERCC2 (Wang et al., 1995) . The meaning of these results is not obvious but clearly the interactions of both E2F1 and p53 with ERCC2 and/or ERCC3 and their yeast equivalents is not the same. The interaction of p53 with the two helicase subunits has been demonstrated to be involved in p53-mediated apoptosis and nucleotide excision repair but not transcriptional activation (Wang et al., 1995 (Wang et al., , 1996 . It seems likely that the interaction of activators with dierent subunits of TFIIH mediates dierent cellular functions. Therefore the interactions of activators with the helicase subunits of TFIIH may be involved in apoptosis and other processes, while interactions with the p62 subunit could be involved in transcriptional activation.
The mechanism of transcriptional activation is still not well understood, but the existing evidence suggests that activation domains can contact two or more components of the transcriptional machinery. To cite just one example, the acidic activation domain of VP16 can bind TBP (Stringer et al., 1990) , TFIIB , TAF40 (Goodrich et al., 1993) , PC4 (Ge and Roeder, 1994b) , and the p62 subunit of TFIIH (Xiao et al., 1994) . Furthermore, there are mutations in VP16 that reduce its transactivation potential and simultaneously reduce its binding to TBP (Ingles et al., 1991) and TFIIH (Xiao et al., 1994) . Multiple contacts between activators and general transcription factors may partly explain the synergistic eect of having multiple binding sites for activator proteins in a promoter (Lin et al., 1990) . Furthermore, it is possible that the dierent interactions result in the stimulation of dierent steps in transcription initiation and elongation.
We have shown that E2F1 binds TFIIH as well as TBP. In Western blotting experiments with antiserum against TFIIB, we were only able to detect a trace amount of binding to E2F1 of the TFIIB in a human HeLa cell extract even though VP16 binds TFIIB in this kind of experiment . p53 also does not bind the TFIIB in a HeLa extract (Liu et al., 1993; Xiao et al., 1994) and so strong binding of TFIIB seems not to be a universal feature of acidic activation domains. We have found that the RNA polymerase II holoenzyme (Koleske and Young, 1994; Ossipow et al., 1995) puri®ed from HeLa cell extract (Pan and Greenblatt, manuscript submitted) is able to support transactivation by GAL4-E2F1 (409 ± 437) in vitro (Pearson, unpublished data). Therefore, the small amount of TFIIB present in the E2F1 eluates may be a result of an interaction between RNA polymerase II holoenzyme and the activation domain of E2F1. Analysis of these eluates by Western blot with a monoclonal antibody directed against the carboxyterminal domain of the largest subunit of RNA polymerase II demonstrated that an equally small amount of RNA polymerase II was speci®cally retained on the GST-E2F1 column (data not shown). However, this small amount of RNA polymerase II holoenzyme could not account for the amounts of TFIID and TFIIH we detected in the eluates under these conditions. Our observation that E2F1 binds TBP and TFIIH implies that E2F1 regulates at least two dierent steps in transcription. In certain situations acidic activators like VP16 stimulate recruitment of TFIIB into the assembling transcriptional preinitiation complex . In the case of VP16 it is not clear whether the recruitment of TFIIB is a consequence of the interaction of VP16 with TFIIB or with TBP (Kim et al., 1994a) , but it does seem likely that E2F1's interaction with TBP would also in¯uence an early step in the assembly of the initiation complex. One simple possibility is that E2F1 recruits TBP to the promoter, a step in initiation which can be limiting at some promoters in vivo (Chatterjee and Struhl, 1995; Klages and Strubin, 1995) . Alternatively, interaction of E2F1 with TBP may prevent inhibition by transcriptional repressors that also interact with TBP (Inostroza et al., 1992; Ge and Roeder, 1994a; Goppelt et al., 1996) or lead to recruitment of TFIIB or a form of RNA polymerase II holoenzyme that contains several general initiation factors (Kim et al., 1994b; Koleske and Young, 1994) .
E2F1 is one of a growing number of activator proteins, including VP16, that have not been shown to bind TFIIH (Xiao et al., 1994; Tong et al., 1995; Blau et al., 1996) . VP16 stimulates elongation, as well as initiation, by RNA polymerase II (Yankulov et al., 1994) and, indeed, other experiments have indicated that the abilities of various activators, including E2F1, to bind TFIIH correlate with their eects on elongation downstream of the promoter (Blau et al., 1996) . The tat transactivator protein of HIV-1 stimulates transcription elongation and interacts with TFIIH (Blau et al., 1996) . Tat has also recently been shown to directly stimulate TFIIH to phosphorylate the carboxy-terminal heptapeptide repeat domain (CTD) of the largest subunit of RNA polymerase II (Parada and Roeder, 1996) . Therefore the interaction of E2F1 with TFIIH could somehow increase the eciency of elongation by RNA polymerase II. Alternatively, the interaction of activators with TFIIH might stimulate promoter escape. Deletions of E2F1 that remove the ability to bind TFIIH, but retain the ability to bind TBP (e.g. compare 409 ± 437 with 415 ± 437, or 386 ± 437 with 386 ± 426), retain about 40% of the activation potential. We have tested these deletions of the E2F1 activation domain as fusions with the DNA-binding domain of GAL4 in transfection experiments that were analysed by RNAse protection as described in Blau et al. (1996) . In our conditions we did not detect any reproducible dierences in the abilities of the various deletions to stimulate elongation (data not shown), but we did not test promoter escape.
The binding sites in the E2F1 activation domain for TBP, TFIIH and Rb are shown in Figure 7 . The binding site for Rb (Helin et al., 1992) overlaps both TBP-binding sites and the binding site for TFIIH, suggesting that Rb could block activation by E2F1 by interfering with its interactions with the general initiation factors. Hagemeier et al. (1993) observed an excellent correlation between the eects of mutations in the E2F1 activation domain on the binding of human TBP and their eects on the binding of Rb. This result was interpreted to mean that TBP and Rb make similar contacts with E2F1, but it did not exclude the possibility that these mutations simply disturb the overall structure of the E2F1 activation domain and would have a similar aect on any factor that interacts with it. The competition experiment shown in Figure  10a demonstrates that the interactions of the activation domain of E2F1 with TBP and Rb are mutually exclusive. Because we found that only fragments of E2F1 that retain the ability to bind TBP in our assays can support activation, it is plausible to suggest that Rb can inhibit transactivation by E2F1 by blocking the E2F1/TBP interaction. Our observation that a tumorigenic form of Rb (C706F) is de®cient in this ability to displace TBP from E2F1 is consistent with this model. Since there is also direct competition by Rb and the p62 subunit of TFIIH for binding to E2F1 (Figure  10b ), Rb can block the interaction of E2F1 with two general factors in the basal transcription apparatus.
There is good evidence that Rb which is bound to E2F1 at a promoter can repress activation by other activators (Weintraub et al., 1992) and directly block their interactions with TBP and TFIID (Weintraub et al., 1995) . This repression would not be eective if the E2F1 in the complex could itself activate transcription. Remarkably, Rb can simultaneously bind E2F1 and other activators and simultaneously block their interactions with the general initiation factors, leading to ecient repression.
In other experiments (data not shown) we found that the E2F1 activation domain, like those of VP16, p53, and GAL4 (He et al., 1993) could also bind RPA and that the E2F1/RPA interaction was also inhibited by Rb. E2F1 stimulates cells to enter S-phase and may, like other activators (reviewed by Stillman, 1989 ) stimulate initiation of DNA replication. Therefore, it is plausible that Rb may inhibit the ability of E2F1 to directly stimulate DNA replication from replication origins that are positioned near E2F-binding sites. Much more would have to be done to test this hypothesis.
Materials and methods

Plasmid construction
The inserts for making various E2F1 fusion constructs were made by PCR. The following primers were used:
primer #1: 5'-CCCGGATCCCATGTGCGGGAGGACTTC-3 ' primer #2:
5'-CCCGGATCCCTCGAGGAGGGCGAG-3 ' primer #3:
5'-CCCGGATCCTGTGACTTTGGGGACCTC-3 ' primer #4:
5'-CCCGAATTCTAGAAGCCCTGTCAGAAA-3 ' primer #5:
5'-CCCGAATTCTAGTCGAAGAGGTCTCTGAT-3 ' primer #6:
5'-CCCGAATTCTAGGCCTCGTGGGGTGGG-3 ' primer #7:
5'-CCCGGATCCTAGAAGCCCTGTCAGAAA-3 ' primer #8:
5'-CCCGGATCCTAGTCGAAGAGGTCTCTGAT-3 ' primer #9:
5'-CCCGGATCCTACTCCTCGAGGCCGAAGT-3 ' primer #10:
5'-CCCGGATCCCTCGACTACCACTTCG-3 ' primer #11:
5'-CCCGGATCCCTCGACGCCCACTTCG-3 ' primer #12:
5'-CCCGGATCCCTCGACTACCCCTTCG-3 ' primer #13:
5'-CCCGGATCCCTCGACTACCACGCCG-3 ' primer #14:
5'-CCCGAATTCTCAGAAATCCAGGGGGGT-3 ' primer #15:
5'-CCCGGATCCTCAGAAATCCAGGGGGGT-3 '
For the construction of plasmids expressing portions of E2F1 fused to glutathione-S-transferase (GST) the appropriate PCR products were digested with EcoRI and BamHI and ligated into the vector pGEX2T (Pharmacia) that had been digested with EcoRI and BamHI. For the construction of plasmids capable of expressing portions of E2F1 fused to the DNA-binding domain of GAL4 (amino acids 1 ± 147) the PCR products were digested with BamHI and inserted into the BamHI site of the mammalian expression vector pBXG-1 (a gift from M Ptashne). The following sets of primers and templates were used to generate the inserts: pGEX2T/E2F1 (386 ± 437): primers 1 and 4; template GST-E2F1 (342 ± 437) plasmid (Helin et al., 1992) ; pGEX2T/E2F1 (415 ± 437): primers 2 and 4; template GST-E2F1 (409 ± 437) plasmid (Helin et al., 1992) ; pGEX2T/E2F1 (415 ± 426): primers 2 and 5; template GST-E2F1 (409 ± 437) plasmid; pGEX2T/E2F1 (415 ± 426): primers 3 and 4; template GST-E2F1 (409 ± 437) plasmid; pGEX2T/ E2F1 (386 ± 408): primers 1 and 6; template GST-E2F1 (342 ± 437) plasmid; pGEX2T/E2F1 (409 ± 437)Y411A: primers 11 and 14: template pCMV-E2F1YA411 ; pGEX2T/E2F1 (409 ± 437) H412P: primers 12 and 14; template pCMV-E2F1HP412 ; pGEX2T/E2F1 (409 ± 437) F413A: primers 13 and 14; template pCMV-E2F1FA413 ; pBXG-1/E2F1 (386 ± 437): primers 1 and 7; template GST-E2F1 (342 ± 437) plasmid; pBXG-1/E2F1 (386 ± 426): primers 1 and 8; template GST-E2F1 (342 ± 437) plasmid; pBXG-1/E2F1 (386 ± 417): primers 1 and 9; template GST-E2F1 (342 ± 437) plasmid; pBXG-1/E2F1 (409 ± 437): primers 10 and 7; template GST-E2F1 (409 ± 437) plasmid; pBXG-1/ E2F1 (415 ± 437): primers 2 and 7; template GST-E2F1 (409 ± 437) plasmid; pBXG-1/E2F1 (415 ± 426): primers 2 and 8; template GST-E2F1 (409 ± 437) plasmid; pBXG-1/E2F1 (427 ± 437): primers 3 and 7; template GST-E2F1 (409 ± 437) plasmid; pBXG-1/E2F1 (409 ± 437) H412P: primers 12 and 15; template pCMV-E2F1HP412.
All constructs were veri®ed by DNA sequencing. The remaining plasmids encoding GST-F2F1 fusion proteins (Helin et al., 1992) and the plasmids encoding the GST-Rb (Kaelin et al., 1991) fusion proteins have been described previously. The reporter construct p1G4-CAT containing one GAL4-binding site was made from the vector pCATPromoter Vector (Promega). Two synthetic oligos were used that when annealed form the binding site for GAL4: 5'-GATCCGGAGTACTGTCCTCCG-3' and 5'-GATCCG-GAGGACAGTACTCCG-3'. The resulting fragments contain overhangs complementary to BamHI ends and they were inserted into the BamHI site of the vector pCAT-Promoter Vector (Promega).
Protein anity chromatography
GST-fusion proteins expressed in E. coli strain DH5a or JM101 and puri®ed as described previously (Smith and Johnson, 1988) were immobilized at 4 mg/ml on glutathione-sepharose beads (Pharmacia). Crude extracts from E. coli cells carrying a plasmid for overproducing yeast TBP (Truant et al., 1993) or a control plasmid pET5a (Novagen) were loaded onto DE52 (Whatman) columns and the¯ow-through fractions were dialyzed against anity chromatography buer (ACB) (10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) pH 7.9, 1 mM EDTA, 2 mM dithiothreitol, 20% glycerol) containing 0.1 M NaCl, and used in anity chromatography experiments (Formosa et al., 1991) . HeLa whole cell extract was prepared as described previously (Sopta et al., 1985) and dialyzed against ACB containing 0.1 M NaCl. Yeast whole cell extract from the strain BJ2168 was prepared as described previously (Woontner and Jaehning, 1989) and dialyzed against ACB containing 0.1 M NaCl. In Figure 10c the Rb protein that was used contained amino acids 379 ± 792. This Rb protein was expressed as a GST-fusion and the GST-portion was cleaved by treatment with thrombin according to the manufacturer's instructions (Pharmacia).
In vitro protein binding experiments
35 S-labeled proteins were synthesized in vitro using the TNT transcription-translation system (Promega) according to the manufacturer's instructions. Plasmids used to program the reticulocyte lysates for expression of the yeast TFIIH subunits were a generous gift from W Feaver and R Kornberg. The T7 expression vector for human p89 was constructed by subcloning the ERCC3 cDNA from the plasmid pcD1 (Weeda et al., 1990) into the vector pET11a. The T7 expression vector for human p62 has been described previously (Fischer et al., 1992) .
Twenty microlitres of glutathione beads containing various GST-E2F1 fusion proteins immobilized at a concentration of 4 mg/ml each were pre-incubated with ACB containing 0.1 M NaCl, 0.5% Triton X-100 and 2 mg/ml of bovine serum albumin (BSA) at 48C for 2 h. The beads were then mixed with 200 ml of diluted reticulocyte lysate containing labeled protein and incubated at 48C for another 2 h. Reticulocyte lysates containing labeled proteins were diluted 20-fold in ACB containing 0.1 M NaCl, 0.5% Triton X-100 and 2 mg/ ml BSA for use in the binding experiments. The beads were washed four times with 500 ml of ACB containing 0.1 M NaCl and 0.5% Triton X-100. Bound proteins were eluted by incubating the beads with 80 ml of ACB containing 1 M NaCl for 45 min.
Far western experiments
Far Western experiments were modi®ed from previously described procedures (Lieberman and Berk, 1991) . The blots were blocked with renaturation buer containing 3% gelatin and then probed in a volume of 15 ml of renaturation buer containing 150 mM KCl to which 10 ml of reticulocyte lysate containing 35 S-methioninelabeled human TBP was added as a probe. The probe was generated in vitro using the TNT transcriptiontranslation system (Promega) using pKB104 DNA as a template (Kao et al., 1990) . After incubating with the probe overnight the blots were washed twice for 20 min in wash buer containing 500 mM KCl. The blots were airdried and exposed to ®lm for 48 h.
Chloramphenicol acetyltransferase (CAT) assays
The Rb-negative cell line C-33A (American Type Culture Collection) (Auersperg, 1964) was used for the transient transfection experiments. Cells were grown in alphaminimal essential medium supplemented with 10% fetal calf serum. For the CAT assays, cells were grown in 60 mm plates to approximately 70% con¯uency. Two hundred nanograms of the indicated GAL4-E2F1 expression plasmid, 1 mg of the reporter construct E1B-CAT, and 1 mg of the RSV b-gal expression plasmid used as an internal control were transfected per plate. The total amount of transfected DNA was kept constant at 8 mg per plate by the addition of the pSVluc plasmid DNA. Cells were transfected using the calcium phosphate method. Cells were incubated with the calcium phosphate/DNA solution for approximately 18 h. They were then washed with phosphate-buered-saline (PBS) and fresh medium was added to the plates. The cells were incubated for another 24 ± 40 h prior to being harvested. Cells were lysed in 100 ml of reporter lysis buer (Promega); 10 microlitres of extract was used for each assay reaction. CAT activity was measured by the¯uor diusion method as described previously (Sleigh, 1986) using [ 3 H]acetyl coenzyme A (Dupont). The acetylated product was isolated by extraction with ethyl acetate and quanti®ed by scintillation counting. The level of CAT activity was normalized to b-galactosidase activity to correct for dierences in transfection eciency. Results were also normalized to the level of expression of the various activator proteins. All results presented represent the average of at least two independent transfection experiments done in duplicate.
Immunoprecipitation experiments
To check the level of expression of the various GAL4-E2F1 fusion proteins in C-33A cells, the cells were grown to approximately 70% con¯uency in 100 mm plates. The cells were transfected essentially as described above except that 10 mg of the indicated GAL4-E2F1 expression plasmid and 2 mg of the b-galactosidase reporter construct were transfected. The cells were washed in PBS and lysed in 1 ml per plate of RIPA buer (50 mM Tris pH 7.5%, 1% Triton X-100, 0.5% DOC, 0.1% SDS) containing 500 mM NaCl. Cell lysate was transferred to eppendorf tubes and cellular debris was removed by centrifugation for 10 min at 13 000 r.p.m. at 48C. After lysates were prepared from one plate per construct and twenty microlitres of each lysate were assayed for b-galactosidase activity, 250 ml of the lysates were each incubated with 1 ml of antiserum against the DNA-binding domain of GAL4 (UBI) for 1 h at 48C. We then added 30 ml of a 1 : 2 (vol/vol) slurry of protein Aagarose (Pharmacia) in RIPA buer containing 500 mM NaCl to each tube and incubated them at 48C for another hour. The immune complexes were subsequently washed four times in RIPA buer containing 500 mM NaCl and then 50 ml of 16loading dye was added to each tube. The samples were boiled for 5 min and the eluted proteins were electrophoresed on a 12.5% SDS-polyacrylamide gel followed by Western blot analysis with a monoclonal antibody directed against the DNA-binding domain of GAL4 (Santa Cruz). The amount of sample loaded on the gel was normalized to take into account dierences in transfection eciency as determined by the results of the bgalactosidase assays.
